Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary Intercept Pharmaceuticals Announces Completion of Enrollment in FLINT
NEW YORK, Nov. 12, 2012 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, has been informed by the National Institute of
View HTML
Toggle Summary Intercept Pharmaceuticals to Present Phase 2a Portal Hypertension Data at AASLD's Liver Meeting
NEW YORK, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced initial results from PESTO, an
View HTML
Toggle Summary Intercept Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Intercept Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares NEW YORK, Oct. 15, 2012 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel
View HTML
Toggle Summary Intercept Pharmaceuticals Announces Pricing of Initial Public Offering
Intercept Pharmaceuticals Announces Pricing of Initial Public Offering NEW YORK, Oct. 11, 2012 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases,
View HTML
Toggle Summary Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering New York, NY, September 4, 2012 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat
View HTML
Toggle Summary Intercept Pharmaceuticals Closes $30 Million Series C Financing
OrbiMed’s Jonathan Silverstein and Klaus Veitinger Join Board of Directors
View HTML
Toggle Summary Intercept Pharmaceuticals and Servier Announce Agreement for Intercept's TGR5 Research Program in Type 2 Diabetes View HTML
Toggle Summary Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis View HTML
Toggle Summary Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease View HTML
Toggle Summary Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid View HTML